Stock info

Stock: UCB (Bel 20), ISIN: BE0003739530

Last Price 109.85 Max Price 113.85
Min Price 61.66 1 Year return 54.07
Avg. Target 109.83 Expected Return -0.02 %
Sector Health Care Subsector Pharmaceuticals
Sell 0 Rating Star full 12x12Star full 12x12Star full 12x12Star full 12x12
Hold 6 Concensus Cons holdCons buy
Buy 9
Annual report 2018

UCB Group is an international pharmaceutical company from Belgium. UCB Group has around 12,000 employees. UCB Group products include ‘Keppra’, ‘Xyzal’, ‘Zyrtec’, ‘Nootropil’ and ‘Atarax’. UCB's stocks are traded on the Euronext Brussels and the company is a component of the BEL20.

UCB or Union Chimique Belge is the international bio pharmaceutical conglomerate that has been established on 18 January, 1928 by a Belgium businessman Emmanuel Janssen. The foundation of the company can be considered as a successively done conversion of a hybrid chemical firm into a patient centric pharmaceutical company. The main headquarter of the company is located in Brussels, Belgium and the other North-American headquarter is residing in the outside region of Atlanta, Georgia. The main key personalities of the company are known to be Karel Boone, Chairman and Roch Doliveux, Chief Executive Officer of the company, providing employment to approximately 12,000 people globally. The operating units of the company currently have a presence in around 40 countries with a further aim of making a network of the company and its associated partners as a cross functional industry on location all over the world, majorly focusing on severe diseases.

Shares of the company are being traded on the continuous market of Euronext Brussels, coming to the count of BEL-20 with the revenue generation of 3.4 billion €, as was the case in 2012. The overall possessions of the company come out to be around 8.9 billion € along with the total equity of 4.59 billion € (according to the data of 2010). The main products that have been manufactured by the group includes the names of Metadate, omeprazole, Xyzal, Keppra, Vimpat, Cimzia, Nootropil, Zyrtec and Atarax. There are three of the main segmentation within the structure of UCB, named as Science, People and Patients. Science section consists of Commercial partners, Research partners and In-house R&D. People section focusing on cross functional teams and can be considered as a global knowledge-sharing platform. The third and the last section include patient communities, health care professionals and caregivers. The global network of the company is made with the involvement of many of the partners starting from Biowa, ChemBridge, Evotec, Emerald, Harvard University, K.U. Leuven, Pfizer and ending up to Wilex.

Currently, the company is focusing on two of the main therapeutic fields - Central Nervous System and Immunology. The first part concentrating mainly on Parkinson's and Epilepsy diseases along with the rest-less legs syndrome and the second part is focusing on disorders like bone-loss, lupus, rheumatoid arthritis and Crohn's disease. ‘Braine-l'Alleud’ in Belgium (for CNS disorders) and ‘Slough’ in UK (for immunology department) are the two main Research Centers of Excellence associated with the company. Primary developmental locations have the presence at the locations of Atlanta, Braine-l'Alleud, Tokyo, Slough, Monheim and Research Triangle Park. A virtualized R & D collaborating platform has also been made by implementing the principles of Wikipedia by the group in which multi disciplinary teams (including the members from R&D and supply chain departments), which works for the completion of the projects of the company.

Contact info:Street: Allee de la Recherche, 60Zip Code: 1070 BrussCity: BrusselsCountry: BelgiumPhone: 32 2 559 99 99Website: